MYUNGMOON PHARM CO.,LTD Logo

MYUNGMOON PHARM CO.,LTD

Develops, manufactures, and commercializes prescription & OTC medicines for global markets.

017180 | KO

Overview

Corporate Details

ISIN(s):
KR7017180001
LEI:
Country:
South Korea
Address:
경기도 화성시 향남읍 제약공단2길 26, 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Myungmoon Pharm. Co., Ltd., established in 1983, is a research-based pharmaceutical company engaged in the development, manufacturing, and commercialization of healthcare products. The company's portfolio includes a range of ethical (ETC) prescription drugs and over-the-counter (OTC) medicines. It operates through the entire pharmaceutical value chain, from research and development to the import, export, and distribution of its products. Myungmoon Pharm serves both the domestic South Korean market and international markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-06-25 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 25.7 KB
2025-03-26 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.9 MB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 20.8 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.8 MB
2025-03-14 00:00
Proxy Solicitation & Information Statement
[기재정정]의결권대리행사권유참고서류
Korean 206.9 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 13.7 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 222.5 KB
2025-03-10 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 203.2 KB
2025-02-19 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변경
Korean 14.1 KB
2025-01-09 00:00
Regulatory News Service
신탁계약해지결과보고서
Korean 21.4 KB
2025-01-09 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 25.7 KB
2024-11-20 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 3.9 KB

Automate Your Workflow. Get a real-time feed of all MYUNGMOON PHARM CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MYUNGMOON PHARM CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MYUNGMOON PHARM CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.
Japan
4575
Candel Therapeutics, Inc. Logo
Developing off-the-shelf viral immunotherapies to help the immune system fight solid tumors.
United States of America
CADL
Can-Fite BioPharma Ltd. Logo
Develops oral small-molecule drugs targeting A3AR for oncology and inflammatory diseases.
Israel
CANF
Cannovum Cannabis AG Logo
Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.
Germany
27N0
Canopy Growth Corp Logo
Produces diverse cannabis products for medical and recreational markets globally.
United States of America
CGC
Cantourage Group SE Logo
A European platform producing and distributing medical cannabis products to pharmacies.
Germany
HIGH
CAPRICOR THERAPEUTICS, INC. Logo
Develops cell and exosome-based therapeutics for rare diseases like Duchenne muscular dystrophy.
United States of America
CAPR
CAREGEN CO.,LTD. Logo
Develops patented peptides and growth factors for medical aesthetics, pharma, and anti-aging markets.
South Korea
214370
Caribou Biosciences, Inc. Logo
Uses CRISPR genome editing to create off-the-shelf CAR-T cell therapies for cancer.
United States of America
CRBU
Carisma Therapeutics Inc. Logo
Developing engineered macrophage (CAR-M) therapies for solid tumors and autoimmune diseases.
United States of America
CARM

Talk to a Data Expert

Have a question? We'll get back to you promptly.